|
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Recent evidence suggests that the progression to hormone resistance in some breast tumors is due to mutations in the estrogen receptor (ER).
|
1362141 |
1992 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In this study we investigated IGFBP mRNA expression and IGFBP content in relation to ER content in human breast tumors.
|
1382838 |
1992 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We focused upon this group of patients and have identified a truncated ER which is abundant in some ER+/PgR- breast tumors and which inhibits the binding of wild-type ER to its cognate response element.
|
1728420 |
1992 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In estrogen receptor-positive (ER+) breast tumors, the variant allele was preferentially associated with lower levels of ER, and was clinically correlated with frequent spontaneous abortions.
|
1756270 |
1991 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Variant human breast tumor estrogen receptor with constitutive transcriptional activity.
|
1988075 |
1991 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Using a fragment of the estrogen receptor (ER) cDNA as a probe, Southern blots of HindIII-digested genomic DNA, from breast tumours and non-cancerous tissue, revealed a 1.6 kb hybridizing fragment (1.6KbHF) in 3 out of 30 tumours, and in 31 out of 80 mastectomy samples (16 sectors from each of 5 patients), which was significantly correlated with the absence of progesterone receptor.
|
2018347 |
1991 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Expression of genes coding for pS2, c-erbB2, estrogen receptor and the H23 breast tumor-associated antigen. A comparative analysis in breast cancer.
|
2194831 |
1990 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Furthermore, it has been suggested that EGF-R levels are higher in estrogen receptor negative (ER-) than in ER+ human breast tumors and that EGF-R status may be a prognostic indicator in breast cancer.
|
2206558 |
1990 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
It is concluded that ER gene amplification may be one of the mechanisms underlying the increased ER expression in some breast tumors.
|
2302226 |
1990 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Therefore, this PCR technique may be useful in the detection and cloning of rare ER transcripts from breast tumor biopsy specimens.
|
2332903 |
1990 |
|
Mammary Neoplasms
|
0.500 |
PosttranslationalModification
|
group |
BEFREE |
Estrogen receptor gene methylation in human breast tumors.
|
2354445 |
1990 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
It was found that 89.4% of the ER mRNA-positive breast tumor biopsies had detectable EGF mRNA, whereas only 58.3% of the ER mRNA-negative tumors had detectable EGF mRNA.
|
2364377 |
1990 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
An analysis of the human estrogen receptor (ER) mRNA was performed on 71 human breast tumors using an RNase protection assay.
|
2459605 |
1988 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Initial studies in human breast cancer cell lines suggested a possible association between the absence of one allele and the absence of ER expression; subsequent analysis of allele distribution and frequency in 188 primary human breast tumor biopsies did indeed show a significant but not complete correlation between the absence of one allele and the failure to express ER.
|
2562795 |
1989 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
No rearrangement or amplification of the ER gene was seen in either ER-positive or ER-negative breast tumors.
|
2576351 |
1990 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Thirty to 40% of estrogen receptor (ER) positive human breast tumors are resistant to endocrine therapy.
|
2725532 |
1989 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Since sex steroid hormones and growth factors are known to modulate the proliferation of breast tumors, we have studied the effects of estrogen and progestin, their antagonists, and growth factors on the regulation of estrogen receptor (ER) mRNA and protein levels in T47D breast cancer cells, which contain low levels of ER, and in two sublines of MCF-7 cells which contain high ER levels.
|
2785242 |
1989 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Expression of TGF alpha mRNA was detected in 70% of estrogen receptor positive and negative primary human breast tumors from 40 patients when examined by slot blot and Northern analysis.
|
3047554 |
1988 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Human estrogen receptor messenger RNA variants in both normal and tumor breast tissues.
|
7589776 |
1995 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The growth-inhibitory actions of the pineal hormone, melatonin, on human breast tumor cells and the possible association between this inhibition and melatonin's down-regulation of the estrogen receptor (ER) expression were examined in the ER-positive, estrogen-responsive MCF-7 human breast tumor cell line.
|
7629697 |
1995 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
We amplified exons 1 through 8 of the ER gene in 118 ER-positive and 70 ER-negative primary breast tumors and searched for mutations by single-strand conformation polymorphism analysis, denaturing gradient gel electrophoresis, and DNA sequencing.
|
7861463 |
1995 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Relationship between low estrogen receptor values and other prognostic factors in primary breast tumors.
|
7878527 |
1995 |
|
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
erbB-2 expression in estrogen-receptor-positive breast-tumor cells is regulated by growth-modulatory reagents.
|
7906679 |
1994 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
The response to endocrine therapy is not entirely predictable from the estrogen receptor (ER) and progesterone receptor (PgR) status of primary breast tumors.
|
7913659 |
1994 |
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
To further investigate this phenomenon, expression from the antisense ER vectors was studied in an ER-negative breast tumor cell line, MDA-MB-453.
|
7958984 |
1994 |